Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM9161 in Generalized Myasthenia Gravis
NCT05332210Phase 3Completed
- Sponsor
- Harbour BioMed
- Start
- Jun 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of batoclimab in myasthenia gravis (MG), sponsored by Harbour BioMed. Started Jun 2022; status: completed.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05332210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332210.